Log In
Print
BCIQ
Print
Print this Print this
 

Humalog insulin lispro

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionRecombinant insulin analog
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat diabetes mellitus; Treat Type I and II diabetes
Regulatory Designation EU - Standard Review (Treat Type I and II diabetes)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$166.0M

$10.0M

$156.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today